Image

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Recruiting
18-70 years
All
Phase N/A

Powered by AI

Overview

Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores. This study was designed to evaluate potential clinical benefit of repeated cycles of granulocyte-colony stimulating factor (G-CSF) and DARBEPOETIN versus single cycle on delta change in immunometabolic profile of patients at 6 months assessed in terms of -Change in innate immunity -Monocyte, neutrophils -distribution , function and bioenergetic adaptation .

Description

Aim: To study the efficacy of single vs repeated cycle of Granulocyte Colony Stimulating Factor+ darbopoetin vs standard medical treatmenton immunometabolic profile in patient with early decompensated cirrhosis

Study population:

  • Age 18-70 years
  • Early decompensated cirrhosis MELD \< 16 , CTP \< 9B
  • Uncomplicated ascites
  • A Prospective Randomized Controlled Trial.
  • Single Centre.
  • Open label.
  • Block Randomization will be done , it will be implemented by IWRS method.
  • The study will be conducted in Department of Hepatology, ILBS.

Eligibility

Inclusion Criteria:

  1. Age 18-70 years
  2. Decompensated cirrhosis patients
  3. Uncomplicated ascites,
  4. CTP ≤ 9B and MELD \<16
  5. BM Hematopoietic stem cell reserve \> 0.4
  6. Given informed consent

Exclusion Criteria:

  1. Patients with age less than 18 years or more than 65 years
  2. Lack of informed consent
  3. Patients with a history of serious allergic reactions to the active component, filgrastim, other human granulocyte colony-stimulating factors, or any of the ingredients
  4. Evidence of alcoholic hepatitis/active alcohol abuse last intake ≤ 3 months
  5. Suspected autoimmune hepatitis (ANA/ASMA-positive in titers 1:80 and/ or IgG 1.5 times upper limit of normal),
  6. Hemolytic anaemia -Sickle cell disease or thalassemia
  7. Patients with Grade III ascites /complicated ascites
  8. Patients with large spleen (size ≥ 15cm)
  9. Recent variceal bleeding in less than 42 days
  10. Patients with any focus of sepsis as proven by culture positivity or presence of spontaneous Bacterial Peritonitis (SBP)
  11. H/o Seizures
  12. Hepatocellular Carcinoma (HCC) or other malignancy
  13. Acute Kidney Injury (AKI) with serum Creatinine \>1.5 mg/ dl,
  14. Multi-organ failure,
  15. Hepatic Encephalopathy or prior history of HE in less than 6months
  16. HIV seropositivity,
  17. Uncontrolled essential hypertension, CAD /Stroke
  18. Massive hydrothorax
  19. Pregnancy
  20. Viral etiology of liver disease
  21. Chronic kidney disease
  22. Portal vein thrombosis
  23. Planned for LT
  24. Bone marrow hematopoietic stem cells \< 0.4

Study details
    Decompensated Liver Cirrhosis

NCT07002827

Institute of Liver and Biliary Sciences, India

27 June 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.